Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INS022
MIFTS: 42

in Situ Pulmonary Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for in Situ Pulmonary Adenocarcinoma

About this section

MalaCards integrated aliases for in Situ Pulmonary Adenocarcinoma:

Name: in Situ Pulmonary Adenocarcinoma 12 15
Bronchioloalveolar Adenocarcinoma 74
Bronchioalveolar Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050870
UMLS 74 C0007120
Sources

Summaries for in Situ Pulmonary Adenocarcinoma

About this section
Disease Ontology : 12 A lung cancer that derives from the distal bronchioles or alveoli that initially exhibit a specific non-invasive growth pattern.

MalaCards based summary : in Situ Pulmonary Adenocarcinoma, also known as bronchioloalveolar adenocarcinoma, is related to phacolytic glaucoma and parasitic ichthyosporea infectious disease, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with in Situ Pulmonary Adenocarcinoma is LINC02288 (Long Intergenic Non-Protein Coding RNA 2288), and among its related pathways/superpathways are Glioma and Pathways in cancer. The drugs Gefitinib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and heart, and related phenotypes are homeostasis/metabolism and mortality/aging

Sources

Related Diseases for in Situ Pulmonary Adenocarcinoma

About this section

Diseases related to in Situ Pulmonary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 28)
# Related Disease Score Top Affiliating Genes
1 phacolytic glaucoma 10.1 CD68 SERPINA1
2 parasitic ichthyosporea infectious disease 10.1 CD68 SERPINA1
3 rhinosporidiosis 10.1 CD68 SERPINA1
4 inflammatory mfh 10.1 CD68 SERPINA1
5 supratentorial cancer 10.1 CD44 EGFR PROM1
6 cerebrum cancer 10.0 CD44 EGFR PROM1
7 colonic disease 10.0 CD44 EGFR PROM1
8 gastrointestinal system cancer 10.0 CD44 EGFR PROM1
9 rhinoscleroma 10.0 CD68 SERPINA1
10 reproductive system disease 10.0 CD44 EGFR ESR2
11 nodular tenosynovitis 10.0 CD68 S100A9
12 hodgkin's lymphoma, lymphocytic depletion 10.0 ALK CD68
13 gastrointestinal system disease 9.9 CD44 EGFR SERPINA1
14 diffuse meningeal melanocytosis 9.9 CD68 S100A9
15 lung papillary adenocarcinoma 9.9 ALK EML4
16 pancreas adenocarcinoma 9.8 CD44 EGFR PROM1
17 adenocarcinoma 9.8
18 adenocarcinoma in situ 9.8
19 gastric adenosquamous carcinoma 9.8 CD44 PROM1
20 large intestine cancer 9.8 CD44 EGFR ESR2 PROM1
21 adult xanthogranuloma 9.8 CD68 S100A9 SERPINA1
22 reticulohistiocytic granuloma 9.8 CD68 S100A9 SERPINA1
23 lung adenoid cystic carcinoma 9.8 ALK EML4
24 respiratory system cancer 9.8 ALK EGFR EML4
25 congenital epulis 9.7 CD44 CD68 S100A9
26 erythema elevatum diutinum 9.7 CD68 S100A9
27 brain cancer 9.6 ALK CD44 EGFR MSI1
28 respiratory system disease 9.4 ALK EGFR EML4 IL33 SERPINA1

Graphical network of the top 20 diseases related to in Situ Pulmonary Adenocarcinoma:



Diseases related to in Situ Pulmonary Adenocarcinoma
Sources

Symptoms & Phenotypes for in Situ Pulmonary Adenocarcinoma

About this section

UMLS symptoms related to in Situ Pulmonary Adenocarcinoma:


fever, dyspnea, hemoptysis, coughing

MGI Mouse Phenotypes related to in Situ Pulmonary Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ALK ASPH CD44 EGFR ESR2 FGF19
2 mortality/aging MP:0010768 10.21 ALK ASPH CD44 EGFR ESR2 FGF19
3 nervous system MP:0003631 9.96 ALK CD44 EGFR ESR2 FGF19 ITGB1
4 neoplasm MP:0002006 9.87 ALK ASPH CD44 EGFR ESR2 ITGB1
5 no phenotypic analysis MP:0003012 9.7 CD68 EGFR ESR2 HYAL2 IL33 PROM1
6 pigmentation MP:0001186 9.35 ALK CD44 EGFR ITGB1 PROM1
7 skeleton MP:0005390 9.28 ALK CD44 CD68 EGFR ESR2 HYAL2
Sources

Drugs & Therapeutics for in Situ Pulmonary Adenocarcinoma

About this section

Drugs for in Situ Pulmonary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
3
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
7
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
10
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
13
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
16 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
18 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
19 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2,Phase 1
23 Folate Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 3,Phase 2,Phase 1
25 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
26 Vitamin B9 Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31 Antiviral Agents Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
34 Immunoglobulins Phase 2, Phase 3,Phase 1
35 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
36 Antibodies Phase 2, Phase 3,Phase 1
37 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
38 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
39 Mitogens Phase 3,Phase 2
40 Epoetin alfa Phase 3 113427-24-0
41 Hematinics Phase 3,Phase 2
42 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
43
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
44
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
45
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
46
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
47
Promethazine Approved, Investigational Phase 2 60-87-7 4927
48
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
49
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
50
Lomustine Approved, Investigational Phase 2 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
6 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
7 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
8 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
9 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
17 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
18 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
19 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
20 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
21 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
22 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
23 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
24 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
25 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
26 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
27 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
28 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
29 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
30 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
31 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
32 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
33 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
34 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
35 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
36 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
37 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
38 Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00425646 Phase 2 imatinib mesylate
39 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
40 Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
41 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride
42 Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
43 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00234052 Phase 2 carboplatin;pemetrexed
44 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00117962 Phase 2 carboplatin;pemetrexed disodium
45 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
46 Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00081302 Phase 2 carboplatin;paclitaxel
47 Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed NCT00033553 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
48 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
49 Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
50 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin

Search NIH Clinical Center for in Situ Pulmonary Adenocarcinoma

Sources

Genetic Tests for in Situ Pulmonary Adenocarcinoma

About this section
Sources

Anatomical Context for in Situ Pulmonary Adenocarcinoma

About this section

MalaCards organs/tissues related to in Situ Pulmonary Adenocarcinoma:

42
Lung, Brain, Heart, Testes, Endothelial, Smooth Muscle, Colon
Sources

Publications for in Situ Pulmonary Adenocarcinoma

About this section

Articles related to in Situ Pulmonary Adenocarcinoma:

# Title Authors Year
1
Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis. ( 21189386 )
2011
2
A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. ( 20521350 )
2010
3
Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma. ( 18997617 )
2009
4
Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. ( 15362373 )
2004
5
Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? ( 14595748 )
2003
6
Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. ( 11269483 )
2001
7
Expression of alpha-smooth muscle actin in small bronchioloalveolar adenocarcinoma of the lung: assessment and comparison with noguchi criteria. ( 10523684 )
1999
8
Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. ( 9808126 )
1998
9
Bronchioloalveolar adenocarcinoma with myoepithelial cells. ( 1849448 )
1991
Sources

Variations for in Situ Pulmonary Adenocarcinoma

About this section
Sources

Expression for in Situ Pulmonary Adenocarcinoma

About this section
Search GEO for disease gene expression data for in Situ Pulmonary Adenocarcinoma.
Sources

Pathways for in Situ Pulmonary Adenocarcinoma

About this section

Pathways related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Glioma 38
Show member pathways
 12.25 ALK EGFR EML4 ESR2 FGF19
2
Pathways in cancer 38
11.82 ALK EGFR EML4 ESR2 FGF19 ITGB1
3
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.4 CD44 MSI1 PROM1
4
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.38 ITGB1 MSI1 PROM1 SERPINA1
5
Cell adhesion_ECM remodeling 23
11.12 CD44 EGFR ITGB1
6
Signal transduction by L1 67
10.69 EGFR ITGB1
Sources

GO Terms for in Situ Pulmonary Adenocarcinoma

About this section

Cellular components related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.55 CD44 EGFR HYAL2 ITGB1 PROM1
2 apical plasma membrane GO:0016324 9.26 CD44 EGFR HYAL2 PROM1
3 microvillus GO:0005902 8.8 CD44 HYAL2 PROM1

Biological processes related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 9.33 EGFR HYAL2 ITGB1
2 hyaluronan catabolic process GO:0030214 9.26 CD44 HYAL2
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.13 CD44 EGFR FGF19
4 positive regulation of inflammatory response GO:0050729 8.92 EGFR HYAL2 IL33 S100A9

Molecular functions related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 8.8 EGFR HYAL2 ITGB1
Sources

Sources for in Situ Pulmonary Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....